AI summary · may contain errors
Among screening-eligible current smokers in the NLST, low-dose CT screening is linked to 12% lower lung cancer mortality versus chest radiography (HR 0.88, 95% CI 0.79–0.97).
- Open access
Elsevier BV · Oncology · ISSN 1556-0864, 1556-1380
Rebuilt
Newest first · last 60 days
AI summary · may contain errors
Among screening-eligible current smokers in the NLST, low-dose CT screening is linked to 12% lower lung cancer mortality versus chest radiography (HR 0.88, 95% CI 0.79–0.97).
AI summary · may contain errors
In the PECATI phase 2 trial for platinum-refractory advanced B3-thymoma and thymic carcinoma, median progression-free survival reached 22.1 months with 88.0% 5-month PFS.
AI summary · may contain errors
Baseline PD-L1 and TP53 combined with TSG are linked to very-early progression on first-line osimertinib monotherapy in EGFR-mutant NSCLC, with PD-L1 TPS showing the strongest signal.
AI summary · may contain errors
Soxataltinib produced an IRC-assessed 84.8% ORR (95% CI 76.4–91.0) in treatment-naïve and previously treated advanced RET fusion-positive NSCLC at median 19.3-month follow-up.
AI summary · may contain errors
In a real-world cohort of 265 U.S. patients with small cell lung cancer, tarlatamab achieved a 52.6% disease control rate and median rw-PFS of 2.3 months.
AI summary · may contain errors
Consolidation durvalumab after concurrent chemoradiotherapy in limited-stage small-cell lung cancer is linked to lower extrathoracic progression (20.1% vs 30.1%) and longer time to progression or death.
AI summary · may contain errors
Cemiplimab plus chemotherapy improves 5-year overall survival in previously untreated advanced NSCLC without EGFR, ALK, or ROS1 aberrations, with median OS 21.1 vs 12.9 months.
AI summary · may contain errors
In resected lung adenocarcinoma, TP53 and KRAS mutations predict worse stage I overall survival (HR 2.49 and 1.57), while stage I EGFR mutations predict better outcomes (HR 0.59).
Journals this month
Topics moving, week to 17 Nov 2026
By field